CD33 and acute myeloid leukemia: Several randomized controlled trials have tested the addition of the CD33 antibody-drug conjugate gemtuzumab ozogamicin (GO) to intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia (AML) [1,2,3,4,5,6,7].